Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Plus Therapeutics (PSTV) Shares Repurchased (2024)

Plus Therapeutics has reported Shares Repurchased over the past 1 years, most recently at $374000.0 for Q1 2024.

Quarterly Shares Repurchased changed N/A to $374000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $374000.0 through Dec 2024, changed N/A year-over-year, with the annual reading at $374000.0 for FY2024, 196.83% up from the prior year.
Shares Repurchased was $374000.0 for Q1 2024 at Plus Therapeutics.
Over five years, Shares Repurchased peaked at $374000.0 in Q1 2024 and troughed at $374000.0 in Q1 2024.